1. Home
  2. Towards new therapeutic strategies: Zika-driven oncolysis of brain tumor cells
DEPARTMENT FOR BUSINESS, ENERGY & INDUSTRIAL STRATEGY

Towards new therapeutic strategies: Zika-driven oncolysis of brain tumor cells

IATI Identifier: GB-GOV-13-FUND--GCRF-MR_S01411X_1
Project disclaimer
Disclaimer: The data for this page has been produced from IATI data published by DEPARTMENT FOR BUSINESS, ENERGY & INDUSTRIAL STRATEGY. Please contact them (Show Email Address) if you have any questions about their data.

Description

Brain tumours are amongst the most complicated and expensive types of cancer to treat. Brain tumour cells are typically highly aggressive and invasive, and the available treatment options may not be successful and often have side-effects which leave surviving patients with chronic long-term illnesses or disabilities. The occurrence of CNS tumours are rising in many countries, and Latin American countries such as Brazil now have some of the highest rates of occurrence of these types of cancer. In addition, in many Low and Middle Income Countries (LMICs) such as Brazil, there is very high income inequality which is often associated with disparities in access to proper healthcare; brain cancers require sophisticated and long term treatments and access to appropriate, let alone leading-edge treatments can be highly variable. In this project, our goal is to develop a new therapy against brain tumours called oncolytic viral therapy. This type of anti-tumour therapy makes use of viruses which are able to very specifically infect and destroy cancer cells. Although this type of therapy has been successfully developed for other types of cancer, oncolytic viral therapy has not yet been applied to brain cancers. This project builds on a recent finding made at the University of Sao Paulo in Brazil whereby the Zika virus is able to infect and destroy specific types of brain cancer cell. Zika virus is best known as an infectious mosquito-borne virus that can cause developmental defects in the brains of babies born to women with Zika infection. Brazil has been at the centre of this public health crisis, and much has been learned about how the Zika virus does this over the last few years. The recent discovery of the potential of Zika as a therapeutic agent against brain cancers now raises important questions that we will address in this project. In common with other pathogenic viruses, Zika invades human host cells and then uses the host cell machinery to replicate and produce more virus particles. How this happens in brain tumour cells is entirely unknown. This project aims to understand how proteins produced by the Zika virus interact and control proteins in the host human cells. Preliminary studies have indicated that certain types of brain cancer cell are susceptible to the Zika virus, and others less so. We aim to discover why this is so, and what the specific signatures of susceptible brain tumour cells are. In terms of a future oncolytic viral therapy, answering these questions will allow us to (1) design therapeutics that mimic Zika and (2) understand which brain tumours are best suited to the new therapy, thereby targeting the therapy to those patients who can benefit most. If successful, our project will contribute towards the development of a new therapeutic option that can be used to treat patients with one of the most aggressive forms of cancer. By design, our project will be a collaboration between the University of Sao Paulo, where this discovery was initially made and the University of Southampton. Specific "proteomic" techniques which allow the highly sensitive measurement of thousands of proteins in human cells are used at the University of Southampton, and through this collaboration this technique will be applied to develop Zika as an oncolytic therapy. In addition, cross-training of early career researchers between the partner laboratories will allow the exchange of expertise, and in particular the training of Brazilian researchers in proteomic techniques, an important and very powerful approach with the potential to impact many other biomedical research areas.

Objectives

The Global Challenges Research Fund (GCRF) supports cutting-edge research to address challenges faced by developing countries. The fund addresses the UN sustainable development goals. It aims to maximise the impact of research and innovation to improve lives and opportunity in the developing world.


Location

The country, countries or regions that benefit from this Programme.
Brazil
Disclaimer: Country borders do not necessarily reflect the UK Government's official position.

Status Post-completion

The current stage of the Programme, consistent with the International Aid Transparency Initiative's (IATI) classifications.

Programme Spend

Programme budget and spend to date, as per the amounts loaded in financial system(s), and for which procurement has been finalised.

Participating Organisation(s)

Help with participating organisations

Accountable:Organisation responsible for oversight of the activity

Extending: Organisation that manages the budget on behalf of the funding organisation.

Funding: Organisation which provides funds.

Implementing: Organisations implementing the activity.

Sectors

Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.

Budget

A comparison across financial years of forecast budget and spend to date on the Programme.

Download IATI Data for GB-GOV-13-FUND--GCRF-MR_S01411X_1